Best Practice & Research Clinical Rheumatology
Volume 20, Issue 3 , Pages 559-570 , June 2006

Ankylosing spondylitis: New treatment modalities

References 

  1. Braun J, Bollow M, Remlinger G, et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis and Rheumatism. 1998;41:58–67
  2. Zink A, Braun J, Listing J, et al. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis—results from the German rheumatological database. The Journal of Rheumatology. 2000;27:613–622
  3. Dagfinrud H, Mengshoel AM, Hagen KB, et al. Health status of patients with ankylosing spondylitis: a comparison with the general population. Annals of the Rheumatic Diseases. 2004;63:1605–1610
  4. Gladman DD, Helliwell P, Mease PJ, et al. Assessment of patients with psoriatic arthritis. A review of currently available measures. Arthritis and Rheumatism. 2004;50:24–35
  5. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet. 2002;359:1187–1193
  6. Brandt J, Khariouzov A, Listing J, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis and Rheumatism. 2003;48:1667–1675
  7. Davis JC, van der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor (etanercept) for treating ankylosing spondylitis. A randomized controlled trial. Arthritis and Rheumatism. 2003;48:3230–3236
  8. Gorman JD, Sack KE, Davis JC. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α. The New England Journal of Medicine. 2002;346:1349–1356
  9. Van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis and Rheumatism. 2005;52:582–591
  10. Braun J, Brandt J, Listing J, et al. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Annals of the Rheumatic Diseases. 2005;64:229–234
  11. Braun J, Baraliakos X, Brandt J, et al. Clinical response to long-term therapy with infliximab in patients with ankylosing spondylitis—results after 3 years. Rheumatology (Oxford, England). 2005;44:670–676[Epub 2005 Mar 9]
  12. Van den Bosch F, Devinck M, Kruithof E, et al. A prospective long-term study of the efficacy and safety of infliximab in 107 patients with spondyloarthropathy. Arthritis and Rheumatism. 2004;50(supplement):S611
  13. Feletar M, Brockbank JE, Schentag CT, et al. Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients. Annals of the Rheumatic Diseases. 2004;63:156–161
  14. Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Annals of the Rheumatic Diseases; Published online: 27 January 2005. doi: 10.1136/ard.2004.032268
  15. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis and Rheumatism. 1984;27:361–368
  16. Kruithof E, Van den Bosch F, Beaten D, et al. Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Annals of the Rheumatic Diseases. 2002;61:207–212
  17. Maksymowych WP, Jhangri GS, Lambert RG, et al. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. The Journal of Rheumatology. 2002;29:959–965
  18. Sidiropoulos P, Kritikos HD, Siakka P, et al. Low dose of infliximab is inadequate in most patients with spondylarthropathies. Clinical and Experimental Rheumatology. 2005;23:513–516
  19. Temekonidis TI, Alamanos Y, Nikas S, et al. Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study. Annals of the Rheumatic Diseases. 2003;62:1218–1220
  20. Baraliakos X, Brandt J, Listing J, et al. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Research & Therapy. 2005;7:R439–R444
  21. Braun J, Baraliakos X, Golder W, et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis and Rheumatism. 2003;48:1126–1136
  22. Braun J, Baraliakos X, Listing J, et al. Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab. Rheumatology (Oxford, England). 2005;44:1525–1530[Epub 2005 Aug 9]
  23. Baraliakos X, Wanders A, Listing J, et al. Radiographic progression in patients with ankylosing spondylitis (AS) after 2 years of treatment with the tumour necrosis factor antibody infliximab. Annals of the Rheumatic Diseases. 2005;64:1462–1466
  24. Creemers MCW, Franssen MJAM, van't Hof MA, et al. Assessment of outcome in ankylosing spondylitis: an extended radiographic system. Annals of the Rheumatic Diseases. 2005;64:127–129
  25. Doran MF, Brophy S, MacKay K, et al. Predictors of longterm outcome in ankylosing spondylitis. The Journal of Rheumatology. 2003;30:316–320
  26. Kobelt G, Andlin-Sobocki P, Brophy S, et al. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade). Rheumatology. 2004;43:1158–1166
  27. Marzo-Ortega H, McGonagle D, O'Connor P, Emery P. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondyloarthropathy. A clinical and magnetic resonance study. Arthritis and Rheumatism. 2001;44:2112–2117
  28. Calin A, Dijkmans BAC, Emery P, et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Annals of the Rheumatic Diseases. 2004;63:1594–1600
  29. Davis JC, van der Heijde DM, Braun J, et al. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Annals of the Rheumatic Diseases. 2005;64:1557–1562
  30. Brandt J, Listing J, Haibel H, et al. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology. 2005;44:342–348
  31. Baraliakos X, Davis J, Tsuji W, Braun J. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumour necrosis factor alpha receptor fusion protein etanercept. Arthritis and Rheumatism. 2005;1216–1223
  32. Rudwaleit M, Xaraliakos X, Listing J, et al. Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept. Annals of the Rheumatic Diseases. 2005;64:1305–1310
  33. Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumour necrosis factor agents infliximab and etanercept. Arthritis and Rheumatism. 2005;52:2447–2451
  34. Marzo-Ortega H, McGonagle D, O'Connor P, Emery P. Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis. Annals of the Rheumatic Diseases. 2003;62:74–76
  35. Maillefert JF, Aho LS, El Maghraoui A, et al. Changes in bone density in patients with ankylosing spondylitis: a two-year follow-up study. Osteoporosis International. 2001;12:605–609
  36. Allali F, Breban M, Porcher R, et al. Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor alpha. Annals of the Rheumatic Diseases. 2003;62:347–349
  37. Marzo-Ortega H, McGonagle D, Jarrett S, et al. Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. Annals of the Rheumatic Diseases. 2005;64:1568–1575
  38. Marzo-Ortega H, McGonagle D, Haugeberg G, et al. Bone mineral density improvement in spondyloarthropathy after treatment with etanercept. Annals of the Rheumatic Diseases. 2003;62:1020–1021
  39. Davis JC, Fleishmann R, Molitor J, et al. Effects of etanercept on spinal and hip bone mineral density in patients with ankylosing spondylitis: 24-week data. Arthritis and Rheumatism. 2003;[Abstract 365]
  40. Davis J, Kivitz A, Schiff M, et al. Major clinical response and partial remission in ankylosing spondylitis subjects treated with adalimumab: the ATLAS trial. Arthritis and Rheumatism. 2005;52(supplement):S208
  41. Tan AL, Marzo-Ortega H, O'Connor P, et al. Efficacy of anakinra in active ankylosing spondylitis: a clinical and imaging study. Annals of the Rheumatic Diseases. 2004;63:1041–1045
  42. Haibel H, Rudwaleit M, Listing J, Sieper J. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Annals of the Rheumatic Diseases. 2005;64:296–298
  43. Rudwaleit M, Listing J, Brandt J, et al. Prediction of a major clinical (BASDAI 50) to tumour necrosis factor a blockers in ankylosing spondylitis. Annals of the Rheumatic Diseases. 2004;63:665–670
  44. Braun J, Pham T, Sieper J, et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases. 2003;62:817–824
  45. Braun J, Davis J, Dougados M, et al. First update of the International ASAS Consensus Statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases; Epub 2005 Nov 24.
  46. Feldtkeller E, Khan MA, van der Heijde D, et al. Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatology International. 2003;23:61–66
  47. Van der Linden S, van der Heijde D. Ankylosing spondylitis. Clinical features. Rheumatic Diseases Clinics of North America. 1998;24:663–676
  48. Rudwaleit M, van der Heijde D, Khan MA, et al. How to diagnose axial spondyloarthritis early. Annals of the Rheumatic Diseases. 2004;63:533–535
  49. Sieper J, Rudwaleit M. Early referral recommendations for ankylosing spondylitis (including pre-radiographic and radiographic forms) in primary care. Annals of the Rheumatic Diseases. 2005;64:659–663

PII: S1521-6942(06)00039-8

doi: 10.1016/j.berh.2006.03.009

Best Practice & Research Clinical Rheumatology
Volume 20, Issue 3 , Pages 559-570 , June 2006

Article Tools